A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
An Open-Label Phase ½ Study of INCB039110 in Combination With Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab *BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
A Phase 2, Open Label, 2-Cohort, Multi-center Study of INCB50465, a P13K Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with or Without a BTK Inhibitor
